Under terms of the deal, Gilgamesh could receive up to $1.2 billion as bretisilocin progresses through clinical development ...

BeOne Medicines entered a deal worth up to $950 million with Royalty Pharma selling its rights to global sales royalties of ...

The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple ...

The science behind NAMs is evolving rapidly, offering innovative, ethically motivated approaches that can enrich mechanistic ...

Michael Grosberg, vice president of product management, spoke with Pharmaceutical Executive about direct-to-consumer sales ...

Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea ...

Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and ...

Lighthouse Pharmaceuticals receives a $49.2 million grant from the National Institute on Aging, aimed at advancing a Phase 2 ...

In a joint statement, 1 the White House and the EU announced the details of what is being called a framework for an agreement ...

Ken Banta, founder and CEO of The Vanguard Network, reveals the mindsets and moves biopharma leaders need to not just ...

The collaboration will leverage Boehringer Ingelheim’s manufacturing expertise to accelerate AnGes’ HGF gene therapy toward ...

The agreement values Mural Oncology at up to $36.2 million, with shareholders set to receive a base cash payment and ...